DOCSLIB.ORG

Specific Phospholipids Are Required to Reconstitute Adenylate Cyclase Solubilized from Rat Brain (Sodium Deoxycholate/Cholesterol Esters) G

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Specific Phospholipids Are Required to Reconstitute Adenylate Cyclase Solubilized from Rat Brain (Sodium Deoxycholate/Cholesterol Esters) G Proc. NatL'Acad. Sci. USA Vol. 78, No. 1, pp. 120-123, January 1981 Biochemistry Specific phospholipids are required to reconstitute adenylate cyclase solubilized from rat brain (sodium deoxycholate/cholesterol esters) G. MATTHEW HEBDON*, HARRY LEVINE III*, NAjI E. SAHYOUN*, CLAUS J. SCHMITGES*, AND PEDRO CUATRECASAS The Wellcome Research Laboratories, Research Triangle Park, North Carolina 27709 Communicated by Solomon H. Snyder, September 16, 1980 ABSTRACT Adenylate cyclase [ATP pyrophosphate-lyase (cy- pholipids or nonionic detergent for activity. The results further clizing), EC 4.6.1.1] was solubilized from a rat brain homogenste support the hypothesis that the activity ofadenylate cyclase may with sodium deoxycholate. This solubilized preparation had no be dependent on the presence of specific phospholipids. detectable enzymic activity with either Mg-ATP or Mn-ATP as substrate. The activity could be restored by addition of either MATERIALS AND METHODS nonionic detergent or certain specific phospholipids. Maximal res- toration of enzyme activity was obtained with Triton X-100, L-a- Materials. [a-32P]ATP and cyclic [2,8-3H]AMP were from phosphatidylcholine, L-a-lysophosphatidylcholine, phosphatidyl- New England Nuclear; alumina, activity 1, was from ICN. Tri- N-monomethylethanolamine, or sphingomyelin. Activity was only ton X-100 was obtained from Packard. Pyruvate kinase was pur- partially restored by phosphatidylethanolamine (40-60%) or chased from Boehringer Mannheim. Phosphatidyl-N-methyl- phosphatidyl-N,N-dimethylethanolamine (10-20%). Other phos- pholipids tested, including phosphatidylserine, phosphatidylgly- ethanolamine (no. 835-8125) and phosphatidylglycerol (no. 835- cerol, phosphatidylinositol, and phosphatidic acid, could not re- 8126) were supplied by GIBCO. The following naturally de- store enzyme activity but, instead, could inhibit the stimulation rived lipids were from Sigma: phosphatidylcholine (P 5763), ly- of enzyme activity by phosphatidylcholine. The restoration of ac- sophosphatidylcholine (L 4129), sphingomyelin (S 7004), phos- tivity by L-a-phosphatidylcholine was inhibited by cholesterol at phatidylserine (P 6641), phosphatidic acid (P 9511), concentrations above 33 mol %, although this effect was not ob- phosphatidylinositol (P 0639), phosphatidylethanolamine (P served with three different esters of cholesterol. These studies suggest a possible specific role of phospholipids in modulating 4513), phosphatidyl-N,N-dimethylethanolamine (P 1634), cho- adenylate cyclase activity. lesterol (CH-S), cholesterol acetate (CH-SA), cholesterol stear- ate (CH-SS), and cholesterol oleate (CH-SO). ATP, phospho- Adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), EC enolpyruvate, and sodium deoxycholate were also obtained 4.6.1.1] is a membrane-bound enzyme (1, 2) that, through the from Sigma. Triolein and 1,3-diolein were purchased from P-L generation of cyclic AMP in response to hormones, exerts pro- Biochemicals. found effects on cellular metabolism (3, 4). Reports have ap- Preparation of Solubilized Adenylate Cyclase; Male rats peared suggesting a role for lipids in modulating the activity of (Sprague-Dawley, 120-170 g) were decapitated and theirbrains membrane-bound enzymes (5, 6). Examples exist where this were removed. Subsequent operations were performed at 0°C. modulation seems to reflect changes in membrane fluidity (7, Each brain was homogenized in 8 vol (vol/wt) of 3 mM MgCl2/ 8) and others where there appears to be a requirement for cer- 3 mM dithiothreitol/50 mM Tris-HCl, pH 8.2, and centrifuged tain specific phospholipids for enzyme activity (9-11). Such in- for 10 min at 40,000 X gm. This procedure was repeated once vestigations have been extended to the study of adenylate cy- and the pellet was then homogenized in 8 vol of 1 mM MgCl2/ clase principally by the direct addition of phospholipids' (or 3 mM dithiothreitol/0.5% deoxycholate/50 mM Tris HCl, pH cholesterol) to cells or membranes by lipic4 fusion or exchange 8.2. The homogenate was incubated at 0°C for 20 min and cen- or by supplemention of the medium of auxotrophic mutant cells trifuged for 40 min at 300,000 x gm.; further centrifugation of with phospholipid precursors (12-15). Although these studies the supernatant for 45 min at 300,000 X gm. did not sediment have yielded much new and interesting information, the added any further enzyme activity. The supernatant, containing sol- lipids may be exerting uncontrolled effects on the metabolism ubilized (but inactive) adenylate cyclase, was retained for fur- of the cells or they may not partition equally throughout the ther study. membrane. Incubation Procedure. Phospholipid in organic solvent was We have reported the solubilization of adenylate cyclase from dried under a stream of dry N2 until the last trace of solvent rat brain and its subsequent incorporation into liposomes of was removed. The phospholipid was dispersed in the deoxy- defined phospholipid composition (16). These-studies showed cholate-solubilized adenylate cyclase preparation with a glass that the enzyme activity in the liposomes was dependent on the rod and a Vortex mixer to give the concentration noted in the particular phospholipids present. One drawback to this study text; this mixture was incubated at 0°C for 20 min prior to assay is the use of nonionic detergents which, themselves, are capable for adenylate cyclase activity. of stimulating activity. In the present investigation we have Incorporation of Adenylate Cyclase into Liposomes. Phos- used sodium deoxycholate to solubilize the enzyme; this prep- pholipid (10 mg/ml) was dispersed in the deoxycholate-solu- aration is totally dependent on addition of certain specific phos- bilized adenylatecyclase (as described above). This mixture was diluted 20- to 40-fold with 50 mM Tris HCl (pH 8.2) and cen- The publication costs ofthis article were defrayed in part by page charge trifuged at 300,000 x gma for 1 hr. The liposomal pellet was payment. This article must therefore be hereby marked "advertise- ment" in accordance with 18 U. S. C. §1734 solely to indicate this fact. * Authors' names arranged in alphabetical order. 120 Downloaded by guest on September 29, 2021 Biochemistry: Hebdon et al. Proc. Nati. Acad. Sci. USA 78 (1981) 121 resuspended in 50 mM Tris-HCI (pH 8.2) and assayed for ade- Table 1. Incorporation of adenylate cyclase into liposomes nylate cyclase activity. Adenylate Adenylate Cyclase Assay. Enzyme activity was measured for cyclase Protein 20 min at 30°C as described (16). The results are the mean of activity, concentration, duplicate determinations. The results presented here are rep- Sample pmol/min mg/mi resentative of several (at least three) separate experiments be- Original brain homogenate 17 13 cause the absolute magnitude of the changes varies somewhat Deoxycholate supernatant 0.5 5.1 (±20%) with different preparations. Because the activity of the Deoxycholate pellet 1.3 7.9 deoxycholate-solubilized enzyme was totally dependent on the Deoxycholate supernatant + nature of the added phospholipid, it did not seem appropriate phosphatidylcholine 36.5 5.1 to express it as specific activity, which may give a misleading Liposomes 45.5 3.0 appearance of purification. Protein Determination. Protein concentration was estimat- Rat brain was homogenized and treated with deoxycholate. Phos- ed by the method of Lowry et aL (17) as modified by Torngvist phatidylcholine (10 mg/ml) was dispersed in the detergent-solubilized enzyme preparation and the liposomes were-collected bycentrifugation and Belfrage (18). (300,000 x g,,,. for 1 hr). All-samples were resuspended to equivalent volumes, and aliquots were taken to measure enzyme activity. RESULTS Effect of Added Nonionic Detergent, Phosphatidylcholine, than either one alone. The activation by lysolecithin, in con- and Lysophosphatidylcholine. Adenylate cyclase solubilized trast, was inhibited by the presence of Triton X-100. from a rat brain homogenate with 0.5% deoxycholate had es- Effects of Other Phospholipids. Phosphatidylserine, phos- sentially no enzymic activity with either Mg2" (see Table 1) or phatidic acid, phosphatidylglycerol, phosphatidylinositol, and Mn2+ as the metal ion cofactor. di- or triglycerides, at 10 mg/ml, wereunable to restore enzyme Fig. 1 shows the effect on enzyme activity of adding increas- activity. Fig. 2 shows the activity obtained at constant lipid con- ing concentrations of Triton X-100, phosphatidylcholine, and centration for phosphatidylcholine in-the presence of increasing lysophosphatidylcholine. The maximal extent of activation with proportions of phosphatidylserine or phosphatidic acid. Both nonionic detergent, phosphatidylcholine, or lysolecithin was of these phospholipids inhibited the reconstitution of activity. about the same as that achieved with sphingomyelin (not Axelrod and his colleagues (19, 20) have proposed a mech- shown). The optimal concentration of lysophosphatidylcholine anism for hormonal activation of adenylate cyclase involving the was about 5 mg/ml; that of the other phospholipids or detergent sequential methylation of phosphatidylethanolamine to phos- was about 10-20 mg/ml. Addition of nonionic detergent plus phatidylcholine. We therefore decided to investigate, the effects phosphatidylcholine gave an activity that was somewhat greater ofphosphatidylethanolamine and the methylated intermediates 38 34 30 26 .E 0 22 ... 6 :6E cQ 182 aW 14 U Q 10 6 2j 100 80 60 40 20 0 0 2 6 10 14 18 22 -Phosphatidylcholine, mol % Phospholipid (detergent),
Load more

Recommended publications
  • Phosphatidylserine
    Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. Phosphatidylserine Evidence Summary May promote cognitive function and protect from decline, especially for DHA-enriched phosphatidylserine. It has a good safety profile but has limited bioavailability. Neuroprotective Benefit: Mixed evidence from clinical trials, and considerable bias in results reporting. Has poor bioavailability and it’s unclear how well it gets into the brain. Aging and related health concerns: No clear rationale or data. One study reported a minor increase in mobility in elderly, but effect can’t be clearly tied to phosphatidylserine. Safety: Well-tolerated with no serious adverse events reported in short trials. May slightly reduce blood pressure. Information on long-term safety is not available. 1 What are they? Phosphatidylserine (PS) is a class of phospholipids that help to make up the plasma membranes in the brain. Varying the levels and the symmetry of PS in cell membranes (i.e. on the inside or outside of a membrane) can affect signaling pathways that are central for cell survival (e.g. Akt, protein kinase C, and Raf-1) and neuronal synaptic communication [1].
    [Show full text]
  • Elimination of GPI2 Suppresses Glycosylphosphatidylinositol Glcnac
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.18.436003; this version posted March 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Elimination of GPI2 suppresses glycosylphosphatidylinositol GlcNAc transferase activity and alters GPI glycan modification in Trypanosoma brucei Aurelio Jenni‡§, SeBastian Knüsel¶, Rupa Nagar||, Mattias Benninger¶, RoBert Häner**, Michael A. J. Ferguson||, IsaBel Roditi¶, Anant K. Menon#, Peter Bütikofer‡1 From the ‡Institute of Biochemistry and Molecular Medicine, University of Bern, 3012 Bern, Switzerland, the §Graduate School for Chemical and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland, the ¶Institute of Cell Biology, University of Bern, 3012 Bern, Switzerland, the ||Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee, United Kingdom, the **Department for Chemistry and Biochemistry, University of Bern, 3012 Bern, Switzerland, the #Department of Biochemistry, Weill Cornell Medical College, New York, New York 10065, USA. Running Title: GPI synthesis in the absence of GPI2 * The work was supported By Swiss National Science Foundation Sinergia grant CRSII5_170923 to RH, AKM and PB, by a Wellcome Tust Investigator Award (101842/Z13/Z) to MAJF and Swiss National Science Foundation grant 310030_184669 to IR. The authors declare that they have no conflicts of interest with the contents of this article. 1 To whom correspondence should Be addressed: Institute of Biochemistry and Molecular Medicine, Bühlstrasse 28, 3012 Bern, Switzerland. Tel.: 41-31-631-4113; E-mail: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.03.18.436003; this version posted March 19, 2021.
    [Show full text]
  • Role of Citicoline in the Management of Traumatic Brain Injury
    pharmaceuticals Review Role of Citicoline in the Management of Traumatic Brain Injury Julio J. Secades Medical Department, Ferrer, 08029 Barcelona, Spain; [email protected] Abstract: Head injury is among the most devastating types of injury, specifically called Traumatic Brain Injury (TBI). There is a need to diminish the morbidity related with TBI and to improve the outcome of patients suffering TBI. Among the improvements in the treatment of TBI, neuroprotection is one of the upcoming improvements. Citicoline has been used in the management of brain ischemia related disorders, such as TBI. Citicoline has biochemical, pharmacological, and pharmacokinetic characteristics that make it a potentially useful neuroprotective drug for the management of TBI. A short review of these characteristics is included in this paper. Moreover, a narrative review of almost all the published or communicated studies performed with this drug in the management of patients with head injury is included. Based on the results obtained in these clinical studies, it is possible to conclude that citicoline is able to accelerate the recovery of consciousness and to improve the outcome of this kind of patient, with an excellent safety profile. Thus, citicoline could have a potential role in the management of TBI. Keywords: CDP-choline; citicoline; pharmacological neuroprotection; brain ischemia; traumatic brain injury; head injury Citation: Secades, J.J. Role of 1. Introduction Citicoline in the Management of Traumatic brain injury (TBI) is among the most devastating types of injury and can Traumatic Brain Injury. result in a different profile of neurological and cognitive deficits, and even death in the most Pharmaceuticals 2021, 14, 410.
    [Show full text]
  • Suramin Alters Phosphoinositide Synthesis and Inhibits Growth Factor Receptor Binding in HT-29 Cells'
    (CANCER RESEARCH 50. 6490-6496. October 15. 1990] Suramin Alters Phosphoinositide Synthesis and Inhibits Growth Factor Receptor Binding in HT-29 Cells' Reinhard Kopp2 and Andreas Pfeiffer Departments of Surgery and Internal Medicine II, Klinikum (irosshadern. University of Munich, West Germany ABSTRACT levels and a stimulation of calcium/calmodulin kinases. Di acylglycerol activates protein kinase C, a family of Ca2+-sensi- Initiation of cell growth frequently involves activation of growth factor tive and phospholipid-dependent isoenzymes, known to phos- receptor-coupled u rosine kinases and stimulation of the phosphoinositide phorylate regulatory proteins and to elevate cytosolic pH levels second messenger system. The antitrypanosomal and antifiliarial drug suramin has been shown to exert antiproliferative activities by inhibition (5, 6). Activation of protein kinase C by phorbol esters and of growth factor receptor binding. We therefore investigated the effect of elevation of intracellular calcium levels by calcium ionophores suramin on epidermal growth factor receptor-binding characteristics and, have been shown to be mitogenically active cofactors during the additionally, searched for effects on basal or cholinergically stimulated initiation of DNA synthesis (7-10). phospholipid metabolism in HT-29 cells. HT-29 colon carcinoma cells have recently been shown to Suramin caused a dose-dependent and noncompetitive inhibition of produce EGF/transforming growth factor «and insulin-like '"I-epidermal growth factor binding (concentration producing 50% inhi growth factor 1-like activities (11), indicating a possible auto bition, 44.2 Mg/ml)but did not alter muscarinic receptor binding. Suramin did not affect the basal '-'I* incorporation into phosphoinositides at crine proliferative effect of these growth factors.
    [Show full text]
  • (4,5) Bisphosphate-Phospholipase C Resynthesis Cycle: Pitps Bridge the ER-PM GAP
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Topological organisation of the phosphatidylinositol (4,5) bisphosphate-phospholipase C resynthesis cycle: PITPs bridge the ER-PM GAP Shamshad Cockcroft and Padinjat Raghu* Dept. of Neuroscience, Physiology and Pharmacology, Division of Biosciences, University College London, London WC1E 6JJ, UK; *National Centre for Biological Sciences, TIFR-GKVK Campus, Bellary Road, Bangalore 560065, India Address correspondence to: Shamshad Cockcroft, University College London UK; Phone: 0044-20-7679-6259; Email: [email protected] Abstract Phospholipase C (PLC) is a receptor-regulated enzyme that hydrolyses phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) at the plasma membrane (PM) triggering three biochemical consequences, the generation of soluble inositol 1,4,5-trisphosphate (IP3), membrane– associated diacylglycerol (DG) and the consumption of plasma membrane PI(4,5)P2. Each of these three signals triggers multiple molecular processes impacting key cellular properties. The activation of PLC also triggers a sequence of biochemical reactions, collectively referred to as the PI(4,5)P2 cycle that culminates in the resynthesis of this lipid. The biochemical intermediates of this cycle and the enzymes that mediate these reactions are topologically distributed across two membrane compartments, the PM and the endoplasmic reticulum (ER). At the plasma membrane, the DG formed during PLC activation is rapidly converted to phosphatidic acid (PA) that needs to be transported to the ER where the machinery for its conversion into PI is localised. Conversely, PI from the ER needs to be rapidly transferred to the plasma membrane where it can be phosphorylated by lipid kinases to regenerate PI(4,5)P2.
    [Show full text]
  • Synthesis of Lysophospholipids
    Molecules 2010, 15, 1354-1377; doi:10.3390/molecules15031354 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Synthesis of Lysophospholipids Paola D’Arrigo 1,2,* and Stefano Servi 1,2 1 Dipartimento di Chimica, Materiali ed Ingegneria Chimica “Giulio Natta”, Politecnico di Milano, Via Mancinelli 7, 20131 Milano, Italy 2 Centro Interuniversitario di Ricerca in Biotecnologie Proteiche "The Protein Factory", Politecnico di Milano and Università degli Studi dell'Insubria, Via Mancinelli 7, 20131 Milano, Italy * Author to whom correspondence should be addressed; E-Mail: paola.d’[email protected]. Received: 17 February 2010; in revised form: 4 March 2010 / Accepted: 5 March 2010 / Published: 8 March 2010 Abstract: New synthetic methods for the preparation of biologically active phospholipids and lysophospholipids (LPLs) are very important in solving problems of membrane–chemistry and biochemistry. Traditionally considered just as second-messenger molecules regulating intracellular signalling pathways, LPLs have recently shown to be involved in many physiological and pathological processes such as inflammation, reproduction, angiogenesis, tumorogenesis, atherosclerosis and nervous system regulation. Elucidation of the mechanistic details involved in the enzymological, cell-biological and membrane-biophysical roles of LPLs relies obviously on the availability of structurally diverse compounds. A variety of chemical and enzymatic routes have been reported in the literature for the synthesis of LPLs: the enzymatic transformation of natural glycerophospholipids (GPLs) using regiospecific enzymes such as phospholipases A1 (PLA1), A2 (PLA2) phospholipase D (PLD) and different lipases, the coupling of enzymatic processes with chemical transformations, the complete chemical synthesis of LPLs starting from glycerol or derivatives. In this review, chemo- enzymatic procedures leading to 1- and 2-LPLs will be described.
    [Show full text]
  • Acetylcholine Signaling System in Progression of Lung Cancers
    Pharmacology & Therapeutics 194 (2019) 222–254 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Acetylcholine signaling system in progression of lung cancers Jamie R. Friedman a,1, Stephen D. Richbart a,1,JustinC.Merritta,KathleenC.Browna, Nicholas A. Nolan a, Austin T. Akers a, Jamie K. Lau b, Zachary R. Robateau a, Sarah L. Miles a,PiyaliDasguptaa,⁎ a Department of Biomedical Sciences, Joan C. Edwards School of Medicine, 1700 Third Avenue, Huntington, WV 25755 b Biology Department, Center for the Sciences, Box 6931, Radford University, Radford, Virginia 24142 article info abstract Available online 3 October 2018 The neurotransmitter acetylcholine (ACh) acts as an autocrine growth factor for human lung cancer. Several lines of evidence show that lung cancer cells express all of the proteins required for the uptake of choline (choline Keywords: transporter 1, choline transporter-like proteins) synthesis of ACh (choline acetyltransferase, carnitine acetyl- Lung cancer transferase), transport of ACh (vesicular acetylcholine transport, OCTs, OCTNs) and degradation of ACh (acetyl- Acetylcholine cholinesterase, butyrylcholinesterase). The released ACh binds back to nicotinic (nAChRs) and muscarinic Cholinergic receptors on lung cancer cells to accelerate their proliferation, migration and invasion. Out of all components Proliferation of the cholinergic pathway, the nAChR-signaling has been studied the most intensely. The reason for this trend Invasion Anti-cancer drugs is due to genome-wide data studies showing that nicotinic receptor subtypes are involved in lung cancer risk, the relationship between cigarette smoke and lung cancer risk as well as the rising popularity of electronic ciga- rettes considered by many as a “safe” alternative to smoking.
    [Show full text]
  • Activation by Inhibition of Second Messenger Compounds
    1230 Annals ofthe Rheumatic Diseases 1992; 51: 1230-1236 Sulphasalazine inhibition of human granulocyte Ann Rheum Dis: first published as 10.1136/ard.51.11.1230 on 1 November 1992. Downloaded from activation by inhibition of second messenger compounds Gunnar Carlin, Richard Djursater, Goran Smedegard Abstract We have previously found by using the The effects of sulphasalazine on the pro- granulocyte as a model system that sulpha- duction of second messenger compounds in salazine inhibits cellular activation before activa- human granulocytes have been characterised tion of protein kinase C by interference with the by various stimuli. The increases in cytosolic synthesis of phosphoinositide derived second calcium, inositol trisphosphate, diacylgly- messenger compounds.6 As several cell types cerol, and phosphatidic acid (all important utilise phosphoinositide dependent signal trans- mediators of intracellular signal transduction) duction, sulphasalazine may modify a principal triggered by stimulation were inhibited by common mechanism for the regulation of sulphasalazine. The metabolites 5-amino- cell activity, which may explain the beneficial salicylic acid and sulphapyridine were less effects of the drug in a variety of diseases. potent inhibitors than the mother compound. Many of the stimuli used in the earlier studies It is concluded that sulphasalazine inhibits trigger an increase in cytosolic calcium as part of the synthesis of phosphoinositide derived the activation sequence. The increase in calcium second messenger compounds at the level of has, in a variety of cell systems, been found to phospholipase C or its regulatory guanosine depend on remodelling of phosphoinositides'3 5'-triphosphate (GTP) binding protein. In- (see fig 1). Ligation of a cell receptor leads to hibition of phosphatidic acid synthesis was the phospholipase C dependent hydrolysis of either due to the same mechanism, or to phosphatidylinositol-4,5-bisphosphate genera- interaction with a phospholipase D regulating ting two triggers of cell responses, namely GTP binding protein.
    [Show full text]
  • Enzyme Phosphatidylserine Synthase (Saccharomyces Cerevisae/Chol Gene/Transformation) V
    Proc. Nati. Acad. Sci. USA Vol. 80, pp. 7279-7283, December 1983 Genetics Isolation of the yeast structural gene for the membrane-associated enzyme phosphatidylserine synthase (Saccharomyces cerevisae/CHOl gene/transformation) V. A. LETTS*, L. S. KLIG*, M. BAE-LEEt, G. M. CARMANt, AND S. A. HENRY* *Departments of Genetics and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461; and tDepartment of Food Science, Cook College, New Jersey Agricultural Experimental Station, Rutgers University, New Brunswick, NJ 08903 Communicated by Frank Lilly, August 11, 1983 ABSTRACT The structural gene (CHOI) for phosphatidyl- Mammals, for example, synthesize PtdSer by an exchange re- serine synthase (CDPdiacylglycerol:L-serine O-phosphatidyl- action with PtdEtn (9). However, PtdSer synthase is found in transferase, EC 2.7.8.8) was isolated by genetic complementation E. coli and indeed the structural gene for the E. coli enzyme has in Saccharomyces cerevmae from a bank of yeast genomic DNA been cloned (10). Thus, cloning of the structural gene for the on a chimeric plasmid. The cloned DNA (4.0 kilobases long) was yeast enzyme will permit a detailed comparison of the structure shown to represent a unique sequence in the yeast genome. The and function of prokaryotic and eukaryotic genes and gene DNA sequence on an integrative plasmid was shown to recombine products. The availability of a clone of the CHOI gene will per- into the CHOi locus, confwrming its genetic identity. The chol yeast mit analysis of its regulation at the transcriptional level. Fur- strain transformed with this gene on an autonomously replicating thermore, the cloning of the CHOI gene provides us with the plasmid had significantly increased activity of the regulated mem- the levels of PtdSer synthase in the cell, brane-associated enzyme phosphatidylserine synthase.
    [Show full text]
  • Alpha-GPC Introduced 2003
    Product Information Sheet – January 2015 Alpha-GPC Introduced 2003 What Is It? Are There Any Potential Drug Interactions? l-Alpha-glycerophophatidylcholine (GPC-choline, alpha-GPC) is a water- At this time, there are no known adverse reactions when taken in soluble phospholipid and neurotransmitter precursor naturally conjunction with medications. occurring in the body. Unlike most membrane phospholipids, alpha- GPC is water-soluble because it lacks the hydrophobic tail groups. Alpha-GPC Uses For Alpha-GPC each Caplique® Capsule contains v 0 • Memory And Cognitive Health: Alpha-GPC passes through the alpha-GPC (L-alpha-glycerophosphatidylcholine) ........................ 200 mg blood brain barrier providing a source of choline for acetylcholine other ingredients: glycerin, water, vegetarian Caplique® Capsule (cellulose, water) and phosphatidylcholine biosynthesis. By supporting cell membrane fluidity and integrity, phosphatidylcholine enhances Contains soy healthy neurotransmitter function and signal transduction. 6 Caplique® Capsules daily, in divided doses, with or Alpha-GPC may support healthy phospholipid turnover in the between meals. brain, helping to counteract age-related cellular breakdown of membrane phospholipids. Acetylcholine is a key neurotransmitter Caplique® Capsule is a registered trademark used by Pure Encapsulations in the brain supporting memory and learning. Optimal under license. phospholipid and acetylcholine levels support cognitive, mental Each Caplique® Capsule is preserved with a nitrogen bubble, which may give the and cerebrovascular health.* appearance of the capsule not being full. Contents may appear cloudy or thick and • Growth Hormone Support: Alpha-GPC has the ability to may settle or separate. potentiate growth hormone releasing hormone (GHRH), thereby supporting healthy growth hormone (GH) levels. The mechanism of support appears to involve increased cholinergic tone.* What Is The Source? Alpha-GPC is derived from highly purified soy lecithin.
    [Show full text]
  • Exploring the Plasmatic Platelet-Activating Factor Acetylhydrolase Activity in Patients with Anti-Phospholipid Antibodies
    Autoimmun Highlights (2017) 8:5 https://doi.org/10.1007/s13317-017-0092-7 ORIGINAL ARTICLE Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies 1,2 1 1 2 Martina Fabris • Adriana Cifu` • Cinzia Pistis • Massimo Siega-Ducaton • 1 1,2 3 1,2 Desre` Ethel Fontana • Roberta Giacomello • Elio Tonutti • Francesco Curcio Received: 23 December 2016 / Accepted: 12 March 2017 / Published online: 25 March 2017 Ó The Author(s) 2017. This article is an open access publication Abstract Conclusions PAF-AH plasmatic activity is particularly up- Purpose To explore the role of plasmatic platelet-activat- regulated in LAC? and in ab2GPI IgG? patients, possibly ing factor acetylhydrolase (PAF-AH), a marker of cardio- representing an alternative prognostic biomarker for the vascular risk, in patients with anti-phospholipid antibodies therapeutic management of APS patients. (aPL). Methods PAF-AH activity was assessed in a series of 167 Keywords Platelet-activating factor acetylhydrolase Á unselected patients screened for aPL in a context of Anti-phospholipid syndrome Á Anti-beta2-glycoprotein I thrombotic events, risk of thrombosis or obstetric compli- antibodies Á Anti-prothrombin/phosphatidylserine cations and in 77 blood donors. antibodies Á Lupus anticoagulant Á Atherosclerosis Results 116/167 patients showed positive results for at least one aPL among IgG/IgM anti-prothrombin/phos- phatidylserine (aPS/PT), anti-cardiolipin (aCL), anti-beta2- Introduction glycoprotein I (ab2GPI) or lupus anticoagulant (LAC), while 51/167 patients resulted aPL-negative. LAC? Anti-phospholipid syndrome (APS) is a hypercoagulable patients disclosed higher PAF-AH than LAC-negative disorder clinically displayed by venous or arterial throm- (22.1 ± 6.4 nmol/min/ml vs.
    [Show full text]
  • Inositol Triphosphate-Triggered Calcium Release Blocks Lipid Exchange at Endoplasmic Reticulum- Golgi Contact Sites
    ARTICLE https://doi.org/10.1038/s41467-021-22882-x OPEN Inositol triphosphate-triggered calcium release blocks lipid exchange at endoplasmic reticulum- Golgi contact sites Mouhannad Malek 1, Anna M. Wawrzyniak 1, Peter Koch1, Christian Lüchtenborg2, Manuel Hessenberger1, ✉ Timo Sachsenheimer2, Wonyul Jang 1, Britta Brügger 2 & Volker Haucke 1,3 fi 1234567890():,; Vesicular traf c and membrane contact sites between organelles enable the exchange of proteins, lipids, and metabolites. Recruitment of tethers to contact sites between the endo- plasmic reticulum (ER) and the plasma membrane is often triggered by calcium. Here we reveal a function for calcium in the repression of cholesterol export at membrane contact sites between the ER and the Golgi complex. We show that calcium efflux from ER stores induced by inositol-triphosphate [IP3] accumulation upon loss of the inositol 5-phosphatase INPP5A or receptor signaling triggers depletion of cholesterol and associated Gb3 from the cell surface, resulting in a blockade of clathrin-independent endocytosis (CIE) of Shiga toxin. This phenotype is caused by the calcium-induced dissociation of oxysterol binding protein (OSBP) from the Golgi complex and from VAP-containing membrane contact sites. Our findings reveal a crucial function for INPP5A-mediated IP3 hydrolysis in the control of lipid exchange at membrane contact sites. 1 Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany. 2 Heidelberg University Biochemistry Center (BZH), Heidelberg ✉ University, Heidelberg, Germany. 3 Faculty of Biology, Chemistry and Pharmacy, Freie Universität Berlin, Berlin, Germany. email: [email protected] NATURE COMMUNICATIONS | (2021) 12:2673 | https://doi.org/10.1038/s41467-021-22882-x | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22882-x ellular membrane homeostasis and the exchange of Results material between compartments can occur by vesicular INPP5A is required for Gb3-mediated Shiga toxin cell entry.
    [Show full text]